EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Mini-review: Evaluation and Management of Retroperitoneal Masses in Patients with Testicular Cancer

Xinyan Yang, Jingqiu Li, Joel Chin, Ravindran Kanesvaran

European Urology Focus · 2024

DOI: 10.1016/j.euf.2024.05.006 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift European Urology Focus, 2024. Verfasst von Xinyan Yang und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Singapore General Hospital, Singapore. Hauptthemen laut MEDLINE: Testicular Neoplasms, Retroperitoneal Neoplasms, Neoplasms, Germ Cell and Embryonal. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 10 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Testicular germ cell tumours (GCTs) account for the majority of testicular malignancies. Seminomas and nonseminomas differ in prognosis and management strategies. While cisplatin-based chemotherapy has significantly improved survival rates, identification of residual masses after chemotherapy is crucial for determining further treatment and survival. For seminomas, spontaneous resolution of residual masses occurs in a significant percentage of cases. Fluorodeoxyglucose positron emission tomography (FDG PET) is recommended for evaluation of residual masses after chemotherapy. Retroperitoneal lymph node dissection (RPLND) offers therapeutic benefits but is challenging because of an increase in desmoplasia after chemotherapy. For nonseminomas, residual masses are common after chemotherapy, with surgical resection necessary for masses larger than 1 cm. FDG PET has limited utility, and timely surgical intervention is crucial for favourable outcomes. Teratoma, if left unresected, can lead to serious complications, including growing teratoma syndrome, malignant transformation, and late relapse. Extraretroperitoneal residual masses, particularly those containing teratoma, are associated with poorer prognosis. Surgical resection remains the mainstay treatment, with significantly higher progression-free and recurrence-free survival rates for fibrosis/necrosis in comparison to teratoma or viable cancer. Understanding the characteristics and management of residual masses after chemotherapy is paramount for optimising treatment strategies and improving patient outcomes in testicular GCT. PATIENT SUMMARY: We reviewed treatment options for patients with testicular cancer who still have tumour tissue in the lower abdomen after chemotherapy. Surgical removal of the tumour is the main option; removal of lymph nodes can also help, but may be difficult because of tissue reactions to chemotherapy. Survival rates differ according to the tumour type and are lower for tumours beyond the lower abdomen.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Testicular NeoplasmsRetroperitoneal NeoplasmsNeoplasms, Germ Cell and EmbryonalHumansMaleSeminomaLymph Node ExcisionTeratomaNeoplasm, Residual

Stichwörter der Autor:innen

Postchemotherapy managementRetroperitoneal massesTesticular cancer

Autor:innen und Institutionen

  • Department of Urology, Singapore General Hospital, Singapore.
  • Duke-NUS Medical School, Singapore, Singapore; Division of Medical Oncology, National Cancer Centre Singapore, Singapore. Electronic address: ravindran.kanesvaran@singhealth.com.sg.

Zitieren

APA

Yang, X., Li, J., Chin, J., & Kanesvaran, R. (2024). Mini-review: Evaluation and Management of Retroperitoneal Masses in Patients with Testicular Cancer. European Urology Focus. https://doi.org/10.1016/j.euf.2024.05.006

Vancouver

Yang X, Li J, Chin J, Kanesvaran R. Mini-review: Evaluation and Management of Retroperitoneal Masses in Patients with Testicular Cancer. European Urology Focus. 2024. doi:10.1016/j.euf.2024.05.006

BibTeX
@article{Yang2024,
  author = {Yang, Xinyan and Li, Jingqiu and Chin, Joel and Kanesvaran, Ravindran},
  title = {Mini-review: Evaluation and Management of Retroperitoneal Masses in Patients with Testicular Cancer},
  journal = {European Urology Focus},
  year = {2024},
  doi = {10.1016/j.euf.2024.05.006}
}
Kostenlos starten →